PBYI
Price
$2.65
Change
+$0.13 (+5.16%)
Updated
Oct 4 closing price
26 days until earnings call
VRCA
Price
$1.31
Change
-$0.14 (-9.66%)
Updated
Oct 4 closing price
33 days until earnings call
Ad is loading...

PBYI vs VRCA

Header iconPBYI vs VRCA Comparison
Open Charts PBYI vs VRCABanner chart's image
Puma Biotechnology
Price$2.65
Change+$0.13 (+5.16%)
Volume$273.14K
CapitalizationN/A
Verrica Pharmaceuticals
Price$1.31
Change-$0.14 (-9.66%)
Volume$1.73M
CapitalizationN/A
View a ticker or compare two or three
PBYI vs VRCA Comparison Chart
Loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
PBYI vs. VRCA commentary
Oct 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a Buy and VRCA is a StrongSell.

COMPARISON
Comparison
Oct 05, 2024
Stock price -- (PBYI: $2.65 vs. VRCA: $1.31)
Brand notoriety: PBYI and VRCA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 72% vs. VRCA: 146%
Market capitalization -- PBYI: $125.07M vs. VRCA: $61.87M
PBYI [@Biotechnology] is valued at $125.07M. VRCA’s [@Biotechnology] market capitalization is $61.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 0 FA rating(s) are green whileVRCA’s FA Score has 0 green FA rating(s).

  • PBYI’s FA Score: 0 green, 5 red.
  • VRCA’s FA Score: 0 green, 5 red.
According to our system of comparison, PBYI is a better buy in the long-term than VRCA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 5 TA indicator(s) are bullish while VRCA’s TA Score has 4 bullish TA indicator(s).

  • PBYI’s TA Score: 5 bullish, 3 bearish.
  • VRCA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, PBYI is a better buy in the short-term than VRCA.

Price Growth

PBYI (@Biotechnology) experienced а +2.91% price change this week, while VRCA (@Biotechnology) price change was -22.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +1.89%, and the average quarterly price growth was -5.77%.

Reported Earning Dates

PBYI is expected to report earnings on Oct 31, 2024.

VRCA is expected to report earnings on Nov 07, 2024.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PBYI($125M) has a higher market cap than VRCA($61.9M). PBYI YTD gains are higher at: -38.684 vs. VRCA (-82.104). PBYI has higher annual earnings (EBITDA): 35.1M vs. VRCA (-77.18M). PBYI has more cash in the bank: 96.8M vs. VRCA (31.9M). VRCA has less debt than PBYI: VRCA (46.3M) vs PBYI (98.6M). PBYI has higher revenues than VRCA: PBYI (219M) vs VRCA (13.9M).
PBYIVRCAPBYI / VRCA
Capitalization125M61.9M202%
EBITDA35.1M-77.18M-45%
Gain YTD-38.684-82.10447%
P/E Ratio13.42N/A-
Revenue219M13.9M1,576%
Total Cash96.8M31.9M303%
Total Debt98.6M46.3M213%
FUNDAMENTALS RATINGS
PBYI vs VRCA: Fundamental Ratings
PBYI
VRCA
OUTLOOK RATING
1..100
2215
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
42100
PRICE GROWTH RATING
1..100
6397
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (56) in the Biotechnology industry is somewhat better than the same rating for VRCA (95) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew somewhat faster than VRCA’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew similarly to VRCA’s over the last 12 months.

PBYI's SMR Rating (42) in the Biotechnology industry is somewhat better than the same rating for VRCA (100) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew somewhat faster than VRCA’s over the last 12 months.

PBYI's Price Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for VRCA (97) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew somewhat faster than VRCA’s over the last 12 months.

PBYI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew similarly to VRCA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIVRCA
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 9 days ago
87%
Declines
ODDS (%)
Bearish Trend 30 days ago
87%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MCHX1.830.02
+1.10%
Marchex
TRNO65.750.63
+0.97%
Terreno Realty Corp
CUBI45.340.30
+0.67%
Customers Bancorp
MELI1960.000.80
+0.04%
MercadoLibre
ESQ61.25-0.08
-0.13%
Esquire Financial Holdings

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with MDGL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
+5.36%
MDGL - PBYI
34%
Loosely correlated
+0.89%
VNDA - PBYI
33%
Loosely correlated
+2.89%
FHTX - PBYI
33%
Poorly correlated
+4.68%
ORMP - PBYI
31%
Poorly correlated
-2.49%
SLRN - PBYI
31%
Poorly correlated
+1.43%
More

VRCA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with TCBP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then TCBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRCA
1D Price
Change %
VRCA100%
-9.66%
TCBP - VRCA
41%
Loosely correlated
+14.83%
SCPX - VRCA
38%
Loosely correlated
+0.55%
DNA - VRCA
33%
Loosely correlated
+2.59%
TNYA - VRCA
30%
Poorly correlated
-6.84%
SLNO - VRCA
29%
Poorly correlated
+1.39%
More